Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,049 across all filing types
Latest filing 2022-11-18 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Transcript of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges referencing a transcript of an earnings call held on November 14, 2022, for the quarter and half year ended September 30, 2022. It states that the transcript has been uploaded on the company's website and requests the exchanges to take the same on record. The document itself does not contain the transcript but is an announcement about the transcript's availability. The document length is short (1641 characters), and it fits the pattern of a Regulatory Filing (RNS) as it is an announcement related to regulatory compliance and disclosure, not the transcript itself. Therefore, it should be classified as Regulatory Filings (RNS).
2022-11-18 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Investors Presentation Glenmark Pharmaceuticals Limited Investor Day 2022' and is addressed to stock exchanges, indicating it is a formal investor communication. The content includes a detailed presentation agenda, company vision, strategic plans, financial targets, ESG ambitions, and business segment details. It is a comprehensive presentation aimed at investors, focusing on financials, strategy, and market position. There is no indication that this is an annual report, earnings release, or regulatory filing. The length (15,000 characters) and detailed content confirm it is the presentation itself, not just an announcement. Therefore, the document fits the category of an Investor Presentation (IP).
2022-11-17 English
Recording of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges confirming the uploading of the audio recording of the Q2 FY 2022-23 Earnings Call on the company's website. It references the earnings call but does not contain the transcript or financial data itself. The document is short (1533 characters) and serves as a notification or confirmation of the availability of the earnings call recording. According to the 'MENU VS MEAL' rule, this is an announcement about the earnings call recording, not the transcript or the earnings release itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a Call Transcript (CT) or Earnings Release (ER).
2022-11-14 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a short notice (1800 characters) informing stock exchanges about an upcoming 'Investor Day' event where senior management will present growth plans. It mentions that presentation materials will be shared closer to the event date. There are no financial statements, detailed financial data, or comprehensive reports included. The document serves as an announcement of an investor presentation event rather than the presentation itself or a detailed report. According to the rules, such announcements about upcoming presentations fall under Investor Presentation (IP) if the presentation is included, but here it is only an announcement of the event and that materials will be shared later. Given the short length and nature, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement informing exchanges about an event, not the presentation or report itself.
2022-11-11 English
Outcome of Board Meeting
Regulatory Filings
2022-11-11 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Call Transcript Classification · 85% confidence The document is an invitation and announcement for an earnings call scheduled on November 14, 2022, for Glenmark Pharmaceuticals' Q2 FY 2022-23 results. It includes dial-in numbers and contact details for registration. There is no actual financial data or detailed financial report included, only the announcement of the call. The document length is short (1897 characters), and it serves as a notice for the upcoming earnings call rather than the transcript or report itself. Therefore, it fits the category of a Call Transcript announcement or invitation, but since it is only an invitation and not the transcript, the best matching category is Call Transcript (CT) as it relates to the earnings call event.
2022-11-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.